Boston Scientific stock costs EUR 37.25 with a 16.98 P/ E

Published on 10/08/2026 at 19:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At EUR 37.25, Boston Scientific stock is 0.75 percent below EUR 37.53. P/E is 16.98, and average volume is 19.71 million shares.

Key points in brief

Boston Scientific stock stood at EUR 37.25 at Lang & Schwarz on October 8, 2026, down 0.75 percent from EUR 37.53.
The NYSE quote was USD 41.72, with a 16.98 price-to-earnings ratio and USD 62.0 billion market capitalization.
Barclays maintained a Hold rating with a USD 48.00 target on October 7, 2026.
Boston Scientific is scheduled to report its next results on October 28, 2026.

Schwarz-Weiß-Reportage: Büroangestellte treten durch Drehtüren eines Bürogebäudes — Boston Properties US1011371077 dokumentiert Angestellte beim Betreten eines klassischen amerikanischen Büroturms in der Innenstadt, Illustration mit AI erstellt.

Boston Scientific (ISIN US1011371077) was trading at EUR 37.25 at Lang & Schwarz on October 8, 2026 at 7:13 p.m. CEST, minus 0.75 percent versus EUR 37.53. The NYSE quote was USD 41.72 at 1:26 p.m. ET on October 8, 2026. Boston Scientific's P/E was 16.98, while its market capitalization was USD 62.0 billion.

Trading range stays near the low

The NYSE session range was USD 41.44 to USD 42.52 on October 8, 2026, against a 52-week range of USD 41.44 to USD 105.65. The latest price therefore stood USD 0.28 above the yearly low, while volume reached 7,472,885 shares versus an average of 19,709,054.

The euro quotation remained below the US dollar range because the two prices use different currencies and venues. The Lang & Schwarz quote is the relevant euro view for German investors, while the NYSE figures place the company in its home market.

Valuation and analyst target

On October 7, 2026, Barclays analyst Matt Miksic maintained a Hold rating and set a USD 48.00 price target, according to Markets Insider. The target lies 15.05 percent above the NYSE price of USD 41.72, using the same currency.

For the quarter ending June 30, 2026, revenue reached USD 5.44 billion versus USD 5.06 billion a year earlier, while net profit rose to USD 907.0 million from USD 793.0 million, according to Markets Insider.

Comparison with peers

Boston Scientific: minus 0.75 percent, P/E 16.98, market capitalization USD 62.0 billion

Medtronic (NYSE, USD): plus 3.32 percent, P/E 21.77, market capitalization USD 113.1 billion

Abbott Laboratories (NYSE, USD): minus 0.22 percent, P/E 31.67, market capitalization USD 170.5 billion

Next results date is October 28

Boston Scientific is scheduled to publish its next results on October 28, 2026, according to Investing.com. The date gives the market a defined checkpoint after the second-quarter revenue of USD 5.44 billion and the current USD 48.00 analyst target.

Boston Scientific quote in euros

Boston Scientific was trading at EUR 37.25 at Lang & Schwarz on October 8, 2026 at 7:13 p.m. CEST, minus 0.75 percent versus the EUR 37.53 prior close of October 7, 2026.

The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.